Serum amyloid P component accelerates the formation and enhances the stability of amyloid fibrils in a physiologically significant under-saturated solution of amyloid-β42

Journal of Alzheimer's Disease

Volumn 29, Issue 4, 2012, Pages 875-881

  Mold, Matthew ^a   Shrive, Annette K ^a   Exley, Christopher ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Aluminum; amyloid fibrils; amyloid ; copper; serum amyloid P component; transmission electron microscopy

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; SERUM AMYLOID P;

ACCELERATION; ARTICLE; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; MEDIATOR; NERVE FIBER; NEUROPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

EID: 84860117142     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120076     Document Type: Article

References (17)

1. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
2. Coria F, Castano E, Prelli F, Larrondollilo M, Vanduinen S, Shelanski ML, Frangione B (1988) Isolation and characterisation of amyloid P-component from Alzheimer's-disease and other types of cerebral amyloidoses. Lab Invest 58, 454-458.
3. Nielsen EH, Nybo M, Junker K, Hansen PT, Rasmussen IM, Svehag SE (2000) Localisation of human serum amyloid P component and heparan sulphate proteoglycan in in vitro-formed Abeta fibrils. Scand J Immunol 52, 110-112.
4. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P-component prevents proteolysis of the amyloid fibrils of Alzheimer-disease and systemic amyloidosis. Proc Natl Acad Sci USA 92, 4299-4303.
5. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lach-mann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259. (Pubitemid 34534701)
6. Shrive AK, Metcalfe AM, Cartwright JR, Greenhough TJ (1999) C-reactive protein and SAP-like pentraxin are both present inLimulus polyphemushaemolymph: Crystal stucture of Limulus SAP. J Mol Biol 290, 997-1008. (Pubitemid 29371735)
7. Sengupta P, Garai K, Sahoo B, Shi Y, Callaway DJE, Maiti S (2003) The amyloid beta peptide (Abeta (1-40)) is thermodynamically soluble at physiological concentrations. Biochemistry 42, 10506-10513. (Pubitemid 37071451)
8. Millar DJ, Hutchinson WL, Pepys MB (2011) Immuno-radiometric assay for human serum amyloid P component. J Immunol Meth 371, 18-24.
9. Shrive AK, Burns I, Chou HT, Stahalberg H, Armstrong PB, Greenhough TJ (2009) Crystal structures of Limulus SAP-pentraxin reveal two molecular aggregations. J Mol Biol 386, 1240-1254.
10. House E, Collingwood J, Khan A, Korchazhkina O, Berthon G, Exley C (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta (42) in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 6, 291-304.
11. House E, Mold M, Collingwood J, Baldwin A, Goodwin S, Exley C (2009) Copper abolishes the beta-sheet secondary structure of preformed amyloid fibrils of A-beta (42). J Alzheimers Dis 18, 811-817.
12. Potempa LA, Kubak BM, Gewurz H (1985) Effect of divalent metal-ions and pH upon the binding reactivity of human-serum amyloid P-component, a c-reactive protein homolog, for zymosan-preferential reactivity in the presence of copper and acidic pH. J Biol Chem 260, 2142-2147.
13. Nielsen EH, Sorensen IJ, Vilsgaard K, Andersen O, Svehag SE (1994) Calcium-enhanced aggregation of serum amyloid P-component and its inhibition by the ligands heparin and heparan sulphate-an electron-microscopic and immunoelec-trophoretic study. APMIS 102, 420-426. (Pubitemid 24266219)
14. Mandelkow E, von Bergen M, Biernat J, Mandelkow EM (2007) Structural priciples of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17, 83-90.
15. Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887, 80-89. (Pubitemid 32008026)
16. Crawford JR, Bjorklund NL, Taglialatella G, Gomer RH (2012) Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer's disease neuropathology. Neurochem Res, doi: 10. 1007/s11064-011- 0674-0.
17. Kolstoe SE, Ridha BH, Belloti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB (2009) Molecular dissection of Alzheimer's disease neu-ropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 106, 7619-7623.